Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 9,698

Document Document Title
WO/2019/008011A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer...  
WO/2019/002175A1
The invention relates to an organic molecule, in particular for use in optoelectronic components. According to the invention, the organic molecule contains - a first chemical unit having a structure of formula (I) and - two second chemic...  
WO/2019/001460A1
The invention relates to a polycyclic compound serving as IRAK4 inhibitor and uses thereof in preparing a drug treating IRAK4-associated diseases. More specifically, the invention relates to said compound represented by formula (I) and a...  
WO/2018/234807A1
The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections. (I)  
WO/2018/234345A1
Compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), and methods of use as lnterleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.  
WO/2018/233684A1
The present invention relates to 7-site substituted pyrrole [2,1-f][1,2,4] triazine compounds or pharmaceutically acceptable salts thereof, and a preparation method therefor and uses thereof. This kind of compound shows good PI3K inhibit...  
WO/2018/220531A1
The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a com...  
WO/2018/218696A1
Provided is a ligand compound ofα7 nicotinic acetylcholine receptor, which can be represented by any one of the following general formulas, wherein (1) represents a halogen. The ligand compound is an improved ligand compound of α7 nico...  
WO/2018/216800A1
The present invention provides: a compound represented by general formula (I) or a salt thereof; an LSD1 inhibitor which contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition which contains the com...  
WO/2018/218197A2
The present invention relates to tetrahydropyrido[4,3-d]pyrimidine based compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.  
WO/2018/218133A1
The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure...  
WO/2018/211275A1
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor ...  
WO/2018/210298A1
The present invention relates to a heteroaryl-pyrazole derivative, and a preparation method therefor and a medical application thereof. Specifically, the present invention relates to a new heteroaryl-pyrazole derivative as shown in formu...  
WO/2018/213211A1
The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X, W, Y, and Z are as defined as set forth in the specification. The present d...  
WO/2018/209667A1
Disclosed in the present invention are crystal forms of a polycyclic heterocyclic compound, preparation methods therefor, applications thereof and a composition thereof. The present invention provides polymorphic forms of a compound of F...  
WO/2018/206820A1
The present invention provides novel heterocyclic compounds of the general formula (I), including novel compounds of formula (la), and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) or (la) and the ph...  
WO/2018/209074A1
Optionally substituted benzoimidazol-1,2-yl amides, such as compounds provided herein (e.g., compounds of Table 1), can be used to treat disorders associated with disorders neuronal excitability, KCNQ channel subunits or mutations in the...  
WO/2018/203194A1
Compounds of Formula (I), pharmaceutical compositions comprising these compounds and their use in treating bacterial infection is disclosed.  
WO/2018/203302A1
This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof that are useful as antibacterial agents. The compounds are useful as inhibitors of bacterial gyrase activity and of b...  
WO/2018/204416A1
The present disclosure relates to rapamycin analogs of the general Formula (I). The compounds are inhibitors of mTOR and thus useful for the treatment of cancer, immune-mediated diseases and age related conditions.  
WO/2018/198077A2
The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined her...  
WO/2018/200425A1
Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering ...  
WO/2018/200855A1
The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, an...  
WO/2018/198844A1
Provided is an organic EL element which exhibits high efficiency and high operational stability, while having low driving voltage. An organic electroluminescent element which has a light emitting layer between a positive electrode and a ...  
WO/2018/195321A1
Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.  
WO/2018/192944A1
A compound of formula I and salts and solvates thereof, wherein: R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', nitro, Me3Sn and halo; where R and R' are independently selected from optionally substituted...  
WO/2018/195243A1
The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formulae (I) and (II). The invention also provides conjugates of the benzodiazepine comp...  
WO/2018/192864A1
The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.  
WO/2018/191476A1
The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in t...  
WO/2018/188346A1
The present invention relates to a water and alcohol soluble triple bonded conjugated polymer and an application thereof in an organic optoelectronic device. The water and alcohol soluble triple bonded conjugated polymer mainly comprises...  
WO/2018/183964A1
Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1 -dependent disorders and enhancing an immune response. Also described are methods of inhibiting ...  
WO/2018/183956A1
Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibitng HPK1, methods of treating ...  
WO/2018/174266A1
Provided is a novel compound which has high antitumor activity, while having low toxicity to normal cells. A pyridone carboxylic acid derivative represented by formula (1) or a salt thereof. (In the formula, R1 represents a hydrogen atom...  
WO/2018/174283A1
Provided is a sustained-release formulation of evocalcet or a pharmacologically acceptable salt thereof. A polyethylene glycol derivative of evocalcet or a pharmacologically acceptable salt thereof is used.  
WO/2018/175474A1
The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds of formula (I) useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of di...  
WO/2018/168232A1
[Problem] A problem was presented in that conventional photochromic compounds cannot be considered adequate in terms of the coloring/decoloring rate and durability, and the production process therefor has many steps. The present inventio...  
WO/2018/168292A1
The purpose of the present invention is to provide: an organic EL element material and a compound, each of which has high luminous efficiency; and an organic EL element, a display device and a lighting device, in each of which the organi...  
WO/2018/167113A1
The invention provides novel compounds having the general formulas (I), (II), wherein R1, R2, Y, W, A, X, m and n are as defined herein, compositions including the compounds and methods of using the compounds.  
WO/2018/167690A1
The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular t...  
WO/2018/161910A1
Disclosed in the present invention is an aminopyrimidine five-membered heterocyclic compound, and an intermediate, preparation method, pharmaceutical composition and application thereof. The aminopyrimidine five-membered heterocyclic com...  
WO/2018/163066A1
The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pha...  
WO/2018/157874A1
Disclosed are a dihydroartemisinin diploid derivative, a pharmaceutical composition thereof, and an application. The derivative is an artemisinin diploid, used for drugs treating or preventing malaria caused by plasmodium, drugs treating...  
WO/2018/153970A1
The present invention covers different solid forms of 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl) -8-(1H-pyrazol-5-yl)-1,7-naphthyridine of formula (I).  
WO/2018/154133A1
The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of ...  
WO/2018/154501A1
The present invention relates to a compound of formula (I), wherein R1, R2, R3 and R4 are each independently hydrogen or Ra, with proviso that a pair of two substituents selected from R1 and R2, R2 and R3, and R3 and R4 is linked to one ...  
WO/2018/153373A1
An azatricyclic compound (as represented by formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of...  
WO/2018/149960A1
The invention relates to aryloxazolidinone compounds of formula I: wherein Y represents hydrogen or certain chemical groups. These compounds are useful antimicrobial agents effective against a variety of pathogens including inter alia Gr...  
WO/2018/152368A1
Provided is a compound of Formula (I), wherein the variable groups are defined herein.  
WO/2018/148576A1
This invention is a benzothiophene estrogen receptor modulator or its pharmaceutically acceptable salt or a pharmaceutically acceptable composition thereof to treat an estrogen-related medical disorder.  
WO/2018/143403A1
Provided is a novel compound or salt thereof that induces degradation by autophagy of an intracellular molecule. In this compound, a ligand having activity to bind to an intracellular molecule and a structure having activity to induce au...  

Matches 1 - 50 out of 9,698